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Ritonavir sulfate is a protease inhibitor widely used in the treatment of acquired immunodeﬁciency
syndrome. In order to elucidate the inherent stability and sensitivity characteristics of ritonavir sulfate, it
was investigated under forced thermal and hydration stress conditions as recommended by the Inter-
national Conference on Harmonization guidelines. In addition, competency of vibrational (infrared and
Raman) spectroscopy was assessed to identify structural changes of the drug symbolizing its stress de-
gradation. High performance liquid chromatography was used as a conﬁrmatory technique for both
thermal and hydration stress study, while thermogravimetric analysis/differential thermal analysis and
atomic force microscopy substantiated the implementation of vibrational spectroscopy in this frame-
work. The results exhibited high thermal stability of the drug as signiﬁcant variations were observed in
the diffuse reﬂectance infrared Fourier transform spectra only after the drug exposure to thermal ra-
diations at 100 °C. Hydration behavior of ritonavir sulfate was evaluated using Raman spectroscopy and
the value of critical relative humidity was found to be 467%. An important aspect of this study was to
utilize vibrational spectroscopic technique to address stability issues of pharmacological molecules, not
only for their processing in pharmaceutical industry, but also for predicting their shelf lives and suitable
storage conditions.
& 2015 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Inhibition of human immunodeﬁciency virus (HIV) protease has
been recognized as an important approach for therapeutic inter-
vention of acquired immunodeﬁciency syndrome (AIDS) [1]. Protease
inhibitors are the drugs which play an instrumental role in the re-
duction of morbidity and mortality among people with HIV infection
[2,3]. Amongst the family of protease inhibitors, ritonavir sulfate has
revolutionized HIV therapy due to its selective, competitive and re-
versible inhibitory effects on both HIV-1 and HIV-2 proteases
[4]. Ritonavir, {[5S-(5R*,8R*,10R*,11R*)]-10-hydroxy-2-methyl-5-(1-
methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis
(phenylmethyl)-2,4,7,12-tetraazatridecan-13-oic acid, 5-thiazolylm-
ethyl ester} (Fig. 1), is a synthetic organic compound derived from
N-carbamoyl-alpha amino acids and their derivatives.
The stability of pharmaceutical molecules is a matter of great
concern as it affects the safety and efﬁcacy of the drug product.
Therefore, the International Conference on Harmonization (ICH)
Q1A guideline entitled “Stability testing of new drug substanceson and hosting by Elsevier B.V. All
University.
a).and products” requires stress testing to be carried out in order to
elucidate the inherent stability and sensitivity characteristics of
the active substance [5]. However, literature supports limited
analytical methods established for the stability studies of the solid
dosage form of ritonavir sulfate. While high performance thin
layer chromatography (HPTLC) has been used for simultaneous
determination of ritonavir and lopinavir in capsules [6]. A few li-
quid chromatography–mass spectroscopy (LC–MS) methods have
been reported for analysis of ritonavir and its metabolites
in biological ﬂuids [7–10]. International Pharmacopoeia (Ph. Int.)
describes a liquid chromatography method to separate ritonavir
and its impurities [4]. Determination of ritonavir in bulk dosage
form using spectrophotometric and potentiometric methods has
also been described [11–15]. In recent years, several high perfor-
mance liquid chromatography (HPLC) methods for simultaneous
determination of antiretroviral drugs in plasma have been de-
monstrated [16,17]. Nevertheless, HPLC has been widely used for
the stress degradation study of pharmaceuticals, it has some dis-
advantages in terms of cost performance, time consumption and
necessary equipment, such as the use of expensive disposable
cartridges at solid-phase drug extraction, gradient elution control
by a gradient HPLC pump system and the ultraviolet detection at
multiple wavelengths. Therefore, in the present scenario, a sim-
pliﬁed technique is desirable for addressing these issues.rights reserved. This is an open access article under the CC BY-NC-ND license
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Fig. 1. Chemical structure of ritonavir sulfate.
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tioned techniques for studying pharmaceutical systems at mole-
cular level as it is a nondestructive and noninvasive technique, and
is sensitive to structural conformational aspects and the environ-
ment of the compound to be analyzed [18]. It also offers sub-
stantial advantages in terms of speed, lends them to in-process
monitoring of the structure and does not require hazardous or-
ganic solvents. Vibrational spectroscopy has been employed by
various researchers to evaluate the photo-stability of drugs. The
photo-stability of nicardipine and corresponding transformations
during the shelf-life of the solid dosage form of a drug has been
determined using Fourier transform infrared (FTIR) spectroscopy
[19]. Similarly, the photo-stability of carbamazepine polymorphs
and nifedipine has been studied using Fourier transform reﬂec-
tion-absorption spectroscopy [20,21]. In our previous study, we
applied diffuse reﬂectance infrared spectroscopy to evaluate the
stability of some antiretroviral and anticancer drugs [22–24]. Ra-
man spectroscopy has been successfully used for the quantitative
analysis of polymorphic mixture of carbamazepine [25]. Sardo
et al. [26] used Raman spectroscopy to monitor reversible-hydra-
tion kinetic processes of niclosamide. Moreover, hydration and
dehydration characteristics of theophylline have been monitored
using Raman spectroscopy [27].
The present study was conducted to assess the feasibility of
vibrational spectroscopy to address thermal as well as hydration
stability issues of ritonavir sulfate. The critical temperature and
critical relative humidity (RH) of ritonavir sulfate estimated
through this work are necessary not only for its processing in
pharmaceutical industry but also for predicting its shelf life and
suitable storage conditions. In this framework, diffuse reﬂectance
infrared Fourier transform (DRIFT) spectroscopy was used to
evaluate the thermal stability of the drug. HPLC and thermo-
gravimetric analysis (TGA)/differential thermal analysis (DTA)
were used to substantiate the inferences drawn from the spec-
troscopic analysis of the thermally degraded drug. Furthermore,
Raman spectroscopy, a water transparent technique, was used to
study the hydration stress behavior of ritonavir, and HPLC was also
used as a conﬁrmatory technique for hydration stress behavior.
Moreover, atomic force microscopy (AFM) analysis was carried out
to depict changes in the topographical morphology of the hy-
drated form of ritonavir sulfate.2. Experimental
2.1. Materials and methods
Tablets of ritonavir sulfate used in this investigation were pro-
cured from Cipla Pharmaceuticals Limited, India. Spectroscopic grade
potassium bromide (KBr) was bought from BDH Laboratory Suppli-
ers, England. Methanol (CH4O), potassium phosphate (KH2PO4),
acetonitrile (C2H3N) and 0.05 M phosphoric acid (H3PO4) used in the
study were of HPLC grade and obtained from Qualigens FineChemicals. Millipore puriﬁed water (resistance 18.2 MΩ) from
Scholar-UV Nex UP 1000 system was used for HPLC analysis. All
other reagents were of analytical grade and used without further
puriﬁcation.2.2. Thermal degradation studies
2.2.1. Sample preparation
Ritonavir sulfate was thermally degraded using Linkam TP 92,
HFS 91/Hot stage plate with platinum resistor. The setup included
a small aluminum dish in which the drug powder was kept on the
silver block in the hot stage. The drug samples for the study were
heated at different temperatures ranging from 30 to 120 °C with
an increment of 10 °C for a period of 1–6 h with an increment of
1 h at each temperature. Besides this, a fresh drug sample was
used at each temperature and retention time. Then, the thermally
treated samples were cooled down to room temperature before
being subjected to DRIFT measurements. The heating and cooling
rate of the hot stage was maintained at 10 °C/min.
2.2.2. DRIFT spectroscopic measurements
To characterize thermally treated ritonavir sulfate samples,
homogenous sample mixtures were prepared by dispersing 5%
(m/m) of thermally treated drug powder in spectroscopic grade
potassium bromide. The sample mixtures were then kept in the
sample holder of Varian 660 Fourier transform infrared spectro-
photometer equipped with Pike Technologies, diffuse reﬂectance
accessory operating with a Globar source, in combination with a
KBr beam splitter and deuterated triglycine sulfate (DTGS) de-
tector. The infrared spectra of the drug powder before and after
exposure to thermal radiation were recorded in the scan range of
400–4000 cm1 with a resolution of 4 cm1. A total of 256 scans
were collected for each spectrum. Background spectrum was also
recorded with ground potassium bromide powder under the same
experimental conditions before collecting each sample scan.
2.2.3. HPLC measurements
HPLC analysis of thermally degraded ritonavir sulfate was
performed on a Shimadzu HPLC (UFLC, Prominence) equipped
with an LC-20AD binary pump, an SPD-20A variable wavelength
UV–vis detector, a CTO-20A column oven, degasser and a manual
injector ﬁtted with 20 mL sample loop. The instrument was con-
trolled by LC software. A Phenomenex C18 column (250 mm
4.6 mm, 5 mm) was used for analysis. The mobile phase consisting
of acetonitrile: 0.05 M phosphoric acid (55:45, v/v), was ultra-
sonicated and vacuum ﬁltered by passing through a 0.44 mm pore
size membrane ﬁlter prior to use. The standard stock solutions of
fresh ritonavir sulfate at a concentration of 1.0 mg/mL, after ex-
posure to thermal radiations and different RH treated samples,
were prepared in the mobile phase. The prepared solution was
ultrasonicated for 20 min, vacuum ﬁltered through a 0.44 mm
membrane ﬁlter and then a 0.22 mm membrane ﬁlter before being
fed to the manual injector. The ﬂow rate was adjusted to 1.0 mL/
min and the injection volume of 20 mL was maintained. All the
chromatograms were recorded at a wavelength of 210 nmwith the
column temperature maintained at 40 °C.
2.2.4. TGA/DTA studies
For comprehensive analysis of ritonavir sulfate's thermal behavior,
TGA/DTA measurements of the drug were conducted on a Shimadzu
TA 60 thermal analyzer with 10 mg of sample under a nitrogen ﬂow of
40 mL/min with a heating rate of 10 °C/min from 35 to 350 °C. The
experiment was performed in triplicate to check the reproducibility.
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2.3.1. Sample preparation
Approximately 0.5 g of the anhydrous ritonavir sulfate samples
were transferred to glass petridishes and exposed to different RH
conditions which were obtained using various saturated salt solu-
tions. The RH values taken from literature [28] were manually opti-
mized and were as follows: 9% (KOH), 13% (LiCl), 20% (KC2H3O2), 28%
(KF), 30% (CaCl2), 42% [Zn (NO3)2], 48% (KSCN), 66% (NaNO2), 73%
(KHSO4), 81% [(NH4)2SO4], 82% (NH4Cl), 86% (Na2SO3), 92% (KNO3).
Similarly, 0% and 100% RH were achieved using silica and millipore
water, respectively. To equilibrate the humidity conditions, each
sample was exposed to different relative humidity for one week. All
the experiments were performed at ambient temperature and re-
peated three times to check its reproducibility.
2.3.2. FT-Raman measurements
The hydration behavior of ritonavir sulfate treated under var-
ious RH conditions, was investigated using Perkin Elmer FT-Raman
spectrophotometer equipped with Nd:YAG laser with an excitation
wavelength of 1064 nm. The laser power was set to 500 mW. A
total of 256 scans were accumulated for each spectrum with a
resolution of 4 cm1.
2.3.3. AFM measurements
For AFM measurements, discs of ritonavir sulfate samples, after
exposure to different RH environments, were prepared by placing
approximately 200 mg of the sample in a press dye at a pressure of
10 t for 5 min. Raman spectroscopy of the discs did not depict any
change in the spectra as a consequence of the applied pressure.
AFM measurements of the discs were performed using Witec
AFM-micro-Raman instrument. All measurements were acquired
in air using tapping mode with silicon cantilevers with a nominal
force constant and resonance frequency of approximately 50 N/m
and 300 kHz, respectively.3. Results and discussion
3.1. Thermal degradation analysis
3.1.1. DRIFT spectroscopic analysis
Ritonavir sulfate was thermally treated at temperatures ranging
from 30 to 120 °C beyond which the physical state of the drug
started changing. The DRIFT spectrum of the thermally untreated
drug in the frequency range of 4000–400 cm1 is shown in Fig. 2.
The characteristic spectrum of fresh ritonavir sulfate showed sharp
peaks at 3085 and 3285 cm1 corresponding to C¼C–HFig. 2. DRIFT spectrum of ritonavir sulfate inasymmetric stretching vibrations of benzene ring and to N–H
stretching vibrations of amide groups, respectively, while those
peaks at 2953, 2918 and 2853 cm1 are due to C–H symmetric and
antisymmetric stretching vibrations of alkanes [29]. The absorp-
tion band owing to the carbonyl group of ester linkage was ob-
served at 1725 cm1[30]. In addition, 1678 cm1 band corres-
ponds to C¼O stretching vibrations of amide group. Similarly,
bands at 1524 and 1496 cm1 can be assigned to C¼C stretching
vibration of aromatic carbons presenting in the benzene ring,
while infrared band at 1461 cm1 is due to C–H3 bending vibra-
tions [29]. Furthermore, the absorption band at 1372 cm1 is at-
tributed to C–H rocking vibration of alkanes. C–O stretching vi-
brations of esters were found in the infrared region 1000 to
1300 cm1[29]. Besides this, the band at 936 cm1 corresponds to
O–H bending vibrations of carboxylic acid. In the frequency range
of 400–900 cm1, out of plane C–H distortions were visible
amongst which the band at 739 cm1 may be due to the presence
of C–H bending vibrations depicting aromatic substitution [31].
The overlaid DRIFT spectra of ritonavir sulfate collected after
exposure to thermal radiations at different temperatures are
shown in Fig. 3 and signiﬁcant changes at higher temperatures in
frequency region of 1800–400 cm-1 are illustrated in Fig. 4. No
major structural changes in terms of infrared band position or
intensity were noticed up to 70 °C, although trivial intensity var-
iations in the region of –OH stretching (3000–4000 cm1) were
observed, which may be attributed to loss of water adsorbed.
Considerable intensity variation was observed in the spectra at
80 °C, which revealed that the drug started degrading around this
temperature. Signiﬁcant changes were detected in the spectra
after exposure at 100 °C for 5 h. The intensity of characteristic
peaks ascribed to ritonavir sulfate started diminishing at the above
mentioned temperature. The higher frequency region attributed to
CH/NH/OH stretching was relatively stable, except for slight in-
tensity variation observed. The intensity of bands at 2953, 2918
and 2853 cm1 which were due to H–C–H symmetric and anti-
symmetric stretching vibrations of alkanes diminished. The infra-
red absorption band at 1725 cm1 owing to the carbonyl group of
ester linkage also vanished. Slight intensity variation was observed
in the band at 936 cm1 which corresponds to O–H bending vi-
brations of carboxylic acid. Besides this, a drop in the intensity was
observed at 1372 and 1239 cm1 bands which correspond to C–H
rocking vibration of alkanes and C–O stretching vibrations of es-
ters, respectively. Similarly, bands at 1117, 1025 and 703 cm1
disappeared whereas a new peak at 444 cm1 originated in the
spectra of degraded drug (inset of Fig. 4). This band may be ten-
tatively assigned to out of plane C–H distortion due to thiazole
moiety [32]. It can be used as a marker band for the degradation of
ritonavir sulfate. Similarly, peaks at 1286 and 845 cm1 owing tothe frequency range of 4000–400 cm1.
Fig. 3. Overlaid DRIFT spectra of ritonavir sulfate in the frequency range of 4000–400 cm1.
Fig. 4. Overlaid DRIFT spectra of ritonavir sulfate at higher temperatures in the region of 1800–400 cm1.
Table 1
Changes in DRIFT frequencies after ritonavir sulfate exposure to higher temperatures and their proposed assignments
Frequency (cm1) Vibrational assignments Remarks
2953 H–C–H symmetric and antisymmetric stretch of alkanes Peaks became less intense at higher temperature.
2918 H–C–H symmetric and antisymmetric stretch of alkanes Intensity of peak decreased.
2853 H–C–H symmetric and antisymmetric stretch of alkanes Peaks became less intense at higher temperature.
1725 C¼O carbonyl group of ester linkage The peak vanished.
1372 C–H rock of alkanes Intensity of peak decreased.
1286 C–O stretch of esters The peak became more intense.
1239 C–O stretch of esters Peaks become less intense at higher temperature.
1117 C–O stretch of esters The peak disappeared at higher temperature.
1025 C–O stretch of esters The peak disappeared.
845 out of plane C–H distortions The peak became more intense.
703 out of plane C–H distortions The peak disappeared.
K. Gambhir et al. / Journal of Pharmaceutical Analysis 5 (2015) 348–355 351C–O stretching vibrations of esters and C–H “oop” modes showed
more intense behavior on degradation. The variations in the band
positions and intensity observed in the infrared spectra of the drug
when exposed to intense thermal radiations are listed in Table 1.
The results of DRIFT spectroscopy presented here showed that
major structural changes took place in ritonavir sulfate after ex-
posure to thermal radiation at 100 °C, whereas it got completely
decomposed after 200 °C. Further, these results indicated higher
thermal stability of the drug as illustrated by TGA/DTA outcomes.
3.1.2. HPLC analysis
HPLC chromatogram of unexposed ritonavir sulfate as shown in
Fig. 5A revealed that the drug was separated at a retention time of
about 6 min. Further, the chromatographic results of thermally
exposed ritonavir remained the same in terms of peak intensityand retention time up to 80 °C, beyond which an additional peak
was observed marking onset of the drug degradation process. And
an additional peak along with a decrease in the characteristic peak
intensity of ritonavir sulfate was observed at 100 °C (exposure
time 5 h) and remained consistent up to 120 °C. Thus, it can be
inferred that maximum degradation was attained at 100 °C, and
HPLC results substantiated DRIFT outcomes. The comparative
chromatogram of thermally exposed (100 °C, 5 h) drug with that of
unexposed drug is shown in Fig. 5B.
3.1.3. TGA/DTA
Ritonavir sulfate was analyzed using TGA/DTA to get an idea
about the thermal decomposition behavior of the drug. In TGA, the
change in sample mass was measured by a thermobalance as a
function of temperature. Fig. 6 shows the TGA curve of ritonavir
Fig. 5. (A) HPLC chromatogram of unexposed ritonavir sulfate and (B) overlaid chromatogram of unexposed and thermally degraded drug at 100 °C at exposure time of 5 h.
Fig. 6. TGA curve of ritonavir sulfate.
K. Gambhir et al. / Journal of Pharmaceutical Analysis 5 (2015) 348–355352sulfate. High thermal stability of the drug can be evident from the
thermal curve as the decomposition started at about 200 °C. The
major weight loss occurred between 220 and 300 °C. DTA curve
was in accordance with TGA results.Fig. 7. Raman spectra of ritonavir sulfat3.2. Hydration studies
3.2.1. Raman analysis
Raman spectrum of anhydrous ritonavir sulfate is shown in
Fig. 7. The band at 1732 cm1 was attributed to the NH⋯O
stretching. The Raman frequency at 1665 cm1 is assigned to the
NH⋯N stretching vibration. The band at 1602 cm1 corresponds
to the amide CO stretching vibration. N¼N stretching was ob-
served at about 1492 cm1[33]. The absorption band at
1230 cm1 is assigned to the C¼O stretching vibration. The ring
stretching was observed at 1205 cm1. O–HN deformation was
observed at 1115 cm1. The Raman frequency at 932 cm1 may be
attributed to symmetric C–O–C stretching. In-plane ring bending
vibration was observed at 750 cm1[33].
Fig. 8 compares the Raman spectra of untreated ritonavir sulfate
with those of collected ones after the drug exposure to RH (82%).
Remarkable differences in terms of band intensity were visible in the
overlaid spectra, which may be associated with the structural changes
induced by hydration. The tentative assignments of the bands where
differences occurred are presented in Table 2.
It can be seen that NH⋯O stretching vibration that appeared at
1732 cm1 in anhydrous form disappears on hydration. The band at
1665 cm1 that is assigned to NH⋯N stretching became less in-
tense and shifted towards lower wavenumber on hydration. N¼Ne in the region of 1800–600 cm1.
Fig. 8. Overlaid Raman spectra of ritonavir sulfate after exposure to high relative humidity.
Table 2
Changes in Raman frequencies after exposing ritonavir sulfate to higher relative humidity and their proposed assignments
Frequency (cm1) Vibrational assignments Remarks
1732 NH⋯O stretching The band disappeared at higher humidity.
1665 NH⋯N stretching Intensity of peak decreased and shifted towards lower wavenumber.
1602 CO amide –
1492 N¼N stretching The band disappeared at higher humidity.
1443 O–H stretching The peak became sharp at higher humidity. It may be due to hydrate formation.
1230 C¼O stretching Intensity of peak decreased.
1205 Ring stretching The peak disappeared.
1115 O⋯NH deformation –
932 Symmetric C–O–C stretch Intensity of peak decreased.
750 In plane ring bending Peak became less intense at higher humidity.
Fig. 9. Overlaid HPLC chromatogram of unexposed and hydrated (82% RH) drugs.
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to higher humidity. O–H stretching peak observed at 1443 cm1 in
anhydrous form became sharp at higher humidity. This may be due
to the hydrogen bonding on hydrate formation. The intensity of
C¼O stretching vibration at 1230 cm1 was decreased after the
drug exposure to higher humidity. The observed shifts may result
from the increase of hydrogen contacts of –OH Group. The struc-
tural changes in the ritonavir sulfate exposure to higher humiditymay be associated with hydrate/pseudo polymorphic transition of
the drug. These results suggested that hydrate formation took place
when the drug is exposed to higher humidity. In addition, structural
changes due to hydrate/pseudo polymorphic transition can easily
be monitored by Raman spectroscopy.
During processing steps like crystallization and lyophilization,
wet granulation and spray-drying pharmaceutical solids may
come in contact with water. Further, the drug substances, which
were subjected to stress conditions (different temperatures and
RH environments) during storage, lead to unexpected hydration
and dehydration phenomena, which affect several drug properties
such as solubility, dissolution rate, stability and bioavailability
[34,35]. The Raman spectra of anhydrous samples stored at dif-
ferent relative humidities showed evidences of the presence of
hydrated samples only after RH467% and all the bands assigned
to anhydrous ritonavir sulfate remained intact up to 65% RH.
3.2.2. HPLC analysis
HPLC chromatogram illustrating hydration behavior of ritonavir
sulfate under water stress condition is shown in Fig. 9. It is evident
that the structure of ritonavir sulfate started changing at about
73% RH. A gradual peak shift to relatively higher retention time
was obtained beyond this RH value, while the drug remained
stable below this humidity condition.
3.2.3. AFM analysis
The surface morphological changes of the anhydrous as well as
hydrated samples of ritonavir sulfate were characterized by AFM. It is
Fig. 10. AFM topographic image of ritonavir sulfate after exposing to different relative humidity environments. (A) anhydrous, (B) 28% RH and (C) 82% RH.
K. Gambhir et al. / Journal of Pharmaceutical Analysis 5 (2015) 348–355354well known that AFM is one of effective ways for the surface analysis
due to its high resolution and powerful analysis software. Fig. 10
shows AFM results before and after the drug exposure to different
relative humidity environments in terms of SDR (signal of dis-
proportionate reporting) percentage. The anhydrous form of ritonavir
sulfate showed SDR 4.76538%, which was eventually reduced to SDR
1.04291% at 82% RH. Therefore, it can be concluded that morphology
of the drug changed as it was exposed to different RH environments,
which may be attributed to hydrate formation.4. Conclusions
The present study assessed the feasibility of vibrational spectro-
scopy to evaluate the thermal stability and hydration behavior of
tablet dosage form of ritonavir sulfate. From DRIFT spectroscopic
investigations, it can be concluded that ritonavir sulfate started de-
grading around 80 °C and got completely degraded at 100 °C. All the
characteristic peaks of ritonavir sulfate diminished signiﬁcantly along
with the emergence of a new peak at 444 cm1 at 100 °C and at all
temperatures beyond it. Similarly, high thermal stability of ritonavir
sulfate is also conﬁrmed through TGA/DTA investigations. Raman
spectroscopic results suggested that the drug underwent structural
transition as a consequence of hydration when exposed to different
RH environments. The value of critical RH for ritonavir sulfate was
found to be 467%. The results of hydration were conﬁrmed by AFM
analysis. In addition, HPLC results were inwell agreement with DRIFT
and Raman spectroscopic inferences accredited to thermal and hy-
dration stress degradation, respectively. Further, this study was car-
ried out to evaluate the stability of ritonavir sulfate under other stress
conditions as deﬁned by ICH guidelines.Acknowledgments
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